AEterna Zentaris

637 articles about AEterna Zentaris

• Aeterna Zentaris Reports Third Quarter 2023 Financial Results

  11/9/2023

  Aeterna Zentaris Inc. reported its financial and operating results for the quarter ended September 30, 2023.

• Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

  10/11/2023

  Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 10:00 AM ET.

• Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  9/5/2023

  Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.

• Aeterna Zentaris Reports Second Quarter 2023 Financial Results

  8/9/2023

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the quarter ended June 30, 2023.

• Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update

  7/13/2023

  Aeterna Zentaris Inc. today provided an update on its therapeutic and diagnostic development pipeline programs and outlined upcoming key milestones.

• Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series

  7/5/2023

  Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer and Eckhard Guenther, PhD, Managing Director and SVP, Business Development of Aeterna Zentaris, will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 13, 2023, at 10:00 AM ET.

• Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

  6/14/2023

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders.

• Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

  5/15/2023

  Aeterna Zentaris Inc. announced that its Virtual Annual General and Special Meeting of Shareholders will be held on June 14, 2023, at 10:00 a.m..

• Aeterna Zentaris Reports First Quarter 2023 Financial Results

  5/9/2023

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the quarter ended March 31, 2023.

• Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

  4/5/2023

  Aeterna Zentaris Inc. today announced that sales of Macrilen® (macimorelin) will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency (“AGHD”), effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner.

• Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

  3/23/2023

  Aeterna Zentaris Inc. today reported its financial and operating results for the year ended December 31, 2022.

• Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

  1/17/2023

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, provided a business update and outlined upcoming key milestones.

• Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

  1/10/2023

  Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 3:00 PM ET.

• Aeterna Zentaris Reports Third Quarter 2022 Financial Results

  11/3/2022

  Aeterna Zentaris Inc. reported its financial and operating results for the third quarter ended September 30, 2022.

• 

  Global Roundup: Clover Progresses Universal COVID-19 Booster, TikoMed Proves Platform in ALS

  9/1/2022

  Clover's SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines. 

• Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

  8/29/2022

  Aeterna Zentaris Inc. today announced that Novo Nordisk Healthcare AG (“Novo Nordisk”), has exercised its right to terminate the amended development and commercialization license agreement (the “CommericalLicense”) previously entered into between Aeterna’s wholly-owned subsidiary and Novo for Macrilen™ (macimorelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

• Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

  8/3/2022

  Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended June 30, 2022 and recent highlights.

• Aeterna Zentaris Announces Effective Date of Share Consolidation - July 18, 2022

  7/18/2022

  Aeterna Zentaris Inc. announced that the Company has filed articles of amendment, to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares.

• Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting - July 06, 2022

  7/6/2022

  Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that the Company has further adjourned its annual general and special meeting of shareholders.

• Aeterna Zentaris Announces Results of Annual Meeting of Shareholders - June 21, 2022

  6/21/2022

  Aeterna Zentaris Inc. announced that all items of business, other than the proposed consolidation of the Company's shares, were approved at its annual meeting of shareholders held today.